New drug aims to stop Alzheimer's before it starts in gene carriers
NCT ID NCT07399171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug HT-4253 can lower Alzheimer's risk in people aged 50-75 who carry the APOE4 gene and have high levels of amyloid in their blood. The 112 participants will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug can shift their amyloid risk score from high to low.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HT-4253
What this could lead to
If successful, this could point toward a way to lower Alzheimer's risk in people with the APOE4 gene variant.
What could go wrong
This is an early Phase 2a trial with only 112 participants, so results may not apply widely. The drug may not improve amyloid risk scores or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates
Contact Phone: •••-•••-•••• Email: •••••@•••••